News and Announcements
AUM Biosciences Establishes Joint Lab with A*STAR’s Singapore Immunology Network (SIgN) to Accelerate the Development of Targeted Cancer Therapies
- Published August 20, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SINGAPORE (18 August 2020) – AUM Biosciences (AUM), a Singapore-headquartered clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology, today announced that together with A*STAR’s Singapore Immunology Network (SIgN), a new joint lab will be established in Singapore, centred on drug development and immuno-monitoring of novel oncology drugs.
Housed in SIgN’s premises at Biopolis, Singapore’s biomedical research hub, the joint lab will focus on the discovery of novel and proprietary immune biomarkers and underlying drug mechanisms of action that will be used to better inform clinical trial design and study endpoint analysis. Combining SIgN’s scientific expertise in translational immunology, preclinical, and computational research with AUM’s extensive capabilities in clinical trial design and management will lead to better-targeted development programs for AUM’s cancer therapies.
Professor Lam Kong Peng, Executive Director of SIgN, added, “We are excited to bring SIgN’s expertise in translational immunology to the joint lab to help accelerate the development of novel cancer therapies, and to support Singapore’s vibrant biotech scene through our collaboration.”
Cancer remains a major medical concern with one in every six deaths being related to the disease. Recent disruptive discoveries in cancer therapy have highlighted the critical role of targeting the host immune system in regulating cancer progression. The AUM – SIgN partnership is timely to synergize drug development and immune profiling efforts to advance the development of multiple small molecules through preclinical and clinical trials with the ultimate goal of bringing these novel oncology drugs to market.
Dr. Harish Dave, CMO of AUM Biosciences, stated “AUM Biosciences is delighted to partner with SIgN in this exciting public-private collaboration. This represents the coming together of the best in translational research and industry to meet a common goal of delivering effective cancer therapeutics to patients.”
Access AUM Biosciences’ Deal Room here.
AUM Biosciences is an award-winning, oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.
The company holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR). AUM’s most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation. For 2 years in a row, the company has been awarded the Frost & Sullivan Asia-Pacific Biotech Entrepreneurial Company of the Year Award.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
